Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Venture Fund Supporting Korea's Bio Start-ups

This article was originally published in PharmAsia News

Executive Summary

Series B financing for the fund's first investment is seen by Novartis as validation for discovery efforts.

You may also be interested in...

Novartis Signs MOU To Invest $100 Million In R&D, Exchanges With Korean Scientists By 2013

SEOUL - Novartis signed a memorandum of understanding with Korea's Ministry for Health, Welfare and Family Affairs to invest $100 million (KRW 125 billion) over the next five years in the research and development of new drugs, scientific exchanges and collaboration in the life sciences

Novartis Korea Venture Fund, OrbiMed Co-lead Series A Financing For South Korean mAb Developer PharmAbcine

SEOUL - Novartis Korea Venture Fund, OrbiMed's Caduceus Asia Partners and local vaccine producer Green Cross plan to invest $6 million in the next three years to support development of PharmAbcine's fully human monoclonal antibodies to treat cancer and inflammatory diseases

Life Sciences Investors Talk Shop On Asia Opportunities – Singapore Conference

SINGAPORE - The swing from big pharma to biotech has captured investor attention, and has changed the nature of the types of investments that venture capitalists are making. Many are willing to take bigger risks in Asia and are opting in earlier rather than as pipelines mature, making intellectual property protection even more critical, a panel of investors said during the BioMedical Asia 2008 conference in Singapore April 15


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts